Một nghiên cứu quan sát tiền cứu về tác động lâm sàng và bệnh lý của xạ trị toàn thân phương pháp chẩn đoán hình ảnh (SBRT) như là một chiến lược hóa trị liệu trước phẫu thuật trong ung thư tụy

International agency for research on Cancer. GLOBOCAN 2012. WHO Am Reg 2012. https://globocan.iarc.fr/old/bar_pop.asp?selection=206826&title=United+Kingdom&sex=0&statistic=0&window=1&grid=1&color1=5&color1e=&color2=4&color2e=&orientation=1&submit=Executr . Accessed 10 Mar 2017). EUROCARE—Survival of cancer patients in Europe n.d. 2010. https://www.eurocare.it/. Accessed 24 July 2018). Gillen S, Schuster T, MeyerzumBüschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7:e1000267. https://doi.org/10.1371/journal.pmed.1000267. Tinchon C, Hubmann E, Pichler A, Keil F, Pichler M, Rabl H, et al. Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma. Acta Oncol (Madr). 2013;52:1231–3. https://doi.org/10.3109/0284186X.2013.771821. Peterson SL, Husnain M, Pollack T, Pimentel A, LoaizaBonilla A, Westendorf-Overley C, et al. Neoadjuvant Nab -paclitaxel and gemcitabine in borderline resectable or locally advanced unresectable pancreatic adenocarcinoma in patients who are ineligible for FOLFIRINOX. Anticancer Res. 2018;38:4035–9. https://doi.org/10.21873/anticanres.12692. Pisters PWT, Abbruzzese JL, Janjan NA, Cleary KR, Charnsangavej C, Goswitz MS, et al. Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol. 1998;16:3843–50. https://doi.org/10.1200/JCO.1998.16.12.3843. Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PWT, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26:3496–502. https://doi.org/10.1200/JCO.2007.15.8634. Esnaola NF, Chaudhary UB, O’Brien P, Garrett-Mayer E, Camp ER, Thomas MB, et al. Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2014;88:837–44. https://doi.org/10.1016/j.ijrobp.2013.12.030. Katz MHG, Shi Q, Ahmad SA, Herman JM, Marsh RDW, Collisson E, et al. Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer alliance for clinical trials in oncology trial A021101. JAMA Surg. 2016. https://doi.org/10.1001/jamasurg.2016.1137. Murphy JE, Wo JY, Ryan DP, Jiang W, Yeap BY, Drapek LC, et al. Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2018;4:963–9. https://doi.org/10.1001/jamaoncol.2018.0329. Huguet F, Hajj C, Winston CB, Shi W, Zhang Z, Wu AJ, et al. Chemotherapy and intensity-modulated radiation therapy for locally advanced pancreatic cancer achieves a high rate of R0 resection. Acta Oncol (Madr). 2017;56:384–90. https://doi.org/10.1080/0284186X.2016.1245862. Koong AC, Le QT, Ho A, Fong B, Fisher G, Cho C, et al. Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2004;58:1017–21. https://doi.org/10.1016/j.ijrobp.2003.11.004. Mellon EA, Hoffe SE, Springett GM, Frakes JM, Strom TJ, Hodul PJ, et al. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta Oncol (Madr). 2015;54:979–85. https://doi.org/10.3109/0284186X.2015.1004367. Mahadevan A, Miksad R, Goldstein M, Sullivan R, Bullock A, Buchbinder E, et al. Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer. Int J Radiat Oncol Biol Phys. 2011;81:e615–e622622. https://doi.org/10.1016/j.ijrobp.2011.04.045. Katz MHG, Ou F-S, Herman JM, Ahmad SA, Wolpin B, Marsh R, et al. Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas. BMC Cancer. 2017;17:505. https://doi.org/10.1186/s12885-017-3441-z. Petrelli F, Comito T, Ghidini A, Torri V, Scorsetti M, Barni S. Stereotactic body radiation therapy for locally advanced pancreatic cancer: a systematic review and pooled analysis of 19 trials. Int J Radiat Oncol Biol Phys. 2017;97:313–22. https://doi.org/10.1016/j.ijrobp.2016.10.030. Stessin AM, Meyer JE, Sherr DL. Neoadjuvant radiation is associated with improved survival in patients with resectable pancreatic cancer: an analysis of data from the surveillance, epidemiology, and end results (SEER) registry. Int J Radiat Oncol Biol Phys. 2008;72:1128–33. https://doi.org/10.1016/j.ijrobp.2008.02.065. Van Tienhoven G, Versteijne E, Suker M, Groothuis KBC, Busch OR, Bonsing BA, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): a randomized, controlled, multicenter phase III trial. J Clin Oncol. 2018;36:LBA4002. https://doi.org/10.1200/jco.2018.36.18_suppl.lba4002. Mokdad AA, Minter RM, Zhu H, Augustine MM, Porembka MR, Wang SC, et al. Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis. J Clin Oncol. 2017;35:515–22. https://doi.org/10.1200/JCO.2016.68.5081 (American Society of Clinical Oncology). Tempero MA, Malafa MP, Behrman SW, Benson AB, Casper ES, Chiorean EG, et al. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2014;12:1083–93. Al-Hawary M, Bain A, Behrman SW, Benson III AB, Binder E, Cardin DB et al. Cassadie Moravek ¥ Pancreatic Cancer Action Network NCCN Guidelines Version 2.2018 Pancreatic Adenocarcinoma. 2018. Tabernero S, Prados S, del Carmen Rubio M, de la Morena F, López M, Sánchez E. REED—Revista Española de Enfermedades Digestivas. Rev Esp Enferm Dig. 2019. https://doi.org/10.17235/reed.2019.5873/2018. Ryan R, Gibbons D, Hyland JMP, Treanor D, White A, Mulcahy HE, et al. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology. 2005;47:141–6. https://doi.org/10.1111/j.1365-2559.2005.02176.x. Cancer Institute N. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. 2009. Chuong MD, Springett GM, Freilich JM, Park CK, Weber JM, Mellon EA, et al. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Int J Radiat Oncol Biol Phys. 2013;86:516–22. https://doi.org/10.1016/j.ijrobp.2013.02.022. Zhong J, Patel K, Switchenko J, Cassidy RJ, Hall WA, Gillespie T, et al. Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation. Cancer. 2017;123:3486–93. https://doi.org/10.1002/cncr.30706. Chuong MD, Frakes JM, Figura N, Hoffe SE, Shridhar R, Mellon EA, et al. Histopathologic tumor response after induction chemotherapy and stereotactic body radiation therapy for borderline resectable pancreatic cancer. J Gastrointest Oncol. 2016;7:221–7. https://doi.org/10.3978/j.issn.2078-6891.2015.075. Chatterjee D, Katz MH, Rashid A, Varadhachary GR, Wolff RA, Wang H, et al. Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma. Cancer. 2012;118:3182–90. https://doi.org/10.1002/cncr.26651.